NCT04233190View on ClinicalTrials.gov

A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

472

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

October 28, 2024

Study Completion Date

October 30, 2024

Conditions
Asthma Copd
Interventions
DRUG

Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg

one inhalation, twice daily

Trial Locations (1)

06696-000

Eurofarma Laboratorios S.A, São Paulo

Sponsors
All Listed Sponsors
lead

Eurofarma Laboratorios S.A.

INDUSTRY